Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Screening for personal or family history of medullary thyroid carcinoma and MEN2 is essential, with patient counseling regarding symptoms such as neck mass, dysphagia, hoarseness, or dyspnea that warrant prompt evaluation
GLP-1 Agonists - Drug Pipeline Therapeutic Assessment This section of the report covers the analysis of GLP-1 agonists drug candidates based on several segmentations, including: By Phase Late-Stage Products (Phase 3 and Phase 4) Mid-Stage Products (Phase 2) Early-Stage Products (Phase I) Preclinical and Discovery Stage Products By Drug Class Peptides Small Molecules mRNA-based Therapies Antibody-Based Therapies By Route of Administration Oral Parenteral Others GLP-1 Agonists - Pipeline Assessment Segmentation, By Phases The report covers phase I, phase II, phase III, phase IV, and early-phase drugs
Dosage frequency depends on your individual goals and your healthcare providers recommendations
Diabetes Care 36 , 10671073 (2013)
US$ 20.39
US$ 28.87
US$ 24.40
US$ 24.19
US$ 23.25
US$ 21.88
US$ 20.15
US$ 21.84
US$ 22.07
US$ 20.58
